Astronics Corporation's $150M note offering led to a 15% drop in stock price. Find out why ATRO stock remains a buy with ...
Axsome Therapeutics (NASDAQ:AXSM) said a long-term Phase 3 study of its drug AXS-12 for the treatment of narcolepsy with cataplexy has met its primary endpoint. The study showed AXS-12 was able to ...
The shares have sprung back to life thanks to China’s new stimulus programs—and Alibaba’s AI ventures. They stand to gain as much as 48%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback